Top Industry Leaders in the Lupus Market
Latest Lupus Companies Updates:
Vera Therapeutics' fusion protein atacicept received fast track designation from the FDA for the treatment of Systemic Lupus Erythematosus (SLE), indicating a potential new therapeutic option for patients.
Aurinia Pharmaceuticals' Lupkynis (voclosporin) continues to gain market share in the LN (lupus nephritis) segment, offering an alternative to traditional immunosuppressants with potentially fewer side effects.
GlaxoSmithKline (GSK) announced positive Phase 2b results for their anti-IL-17A antibody belimumab in combination with standard therapy for SLE, suggesting potential for enhanced efficacy.
Biogen and Zymeworks collaborate on the development of ZW25, a novel bispecific antibody targeting B-cells and T-cells for potential application in SLE.
CytoDyn and Kiniksa Pharmaceuticals are exploring novel pathways and therapeutics for Lupus treatment, offering hope for personalized medicine approaches.
List of Lupus Key companies in the market:
- Aurinia Pharmaceuticals Inc.
- Bristol-Myers Squibb Company
- Cadila Healthcare
- GlaxoSmithKline plc
- Mylan N.V.
- F. Hoffmann-La Roche AG
- Pfizer